Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Mizuho Maintains Outperform on Corvus Pharma, Lowers Price Target to $11

Author: Benzinga Newsdesk | May 20, 2025 08:40am
Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $12 to $11.

Posted In: CRVS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist